Preparation and Evaluation of 5 Fluorouracil solid dispersion formulations for therapeutic management of colorectal cancer (CRC)

Authors

  • Yinka Oyeniyi UDUS Nigeria
  • Nemeka D Nnamani UDUS Nigeria

Keywords:

Solid dispersion, colorectal cancer, 5-Fluorouracil

Abstract

Background A solid dispersion formulation (SD) involves dispersion of poor water soluble active pharmaceutical ingredients (API) in a solubility enhancing polymer with the uttermost goal of improving the oral bioavailability of the API. Objective This study is aimed at production and evaluation of 5- Fluorouracil (5- FU) SD formulations for colon delivery using the hot met technique. Method The solid dispersions of 5-FU were prepared by hot melting method; The SD formulations were characterized using a scanning electron microscopy, USP dissolution apparatus type 2, and MTT assay. Results The SEM revealed that all SD formulations particles were in amorphous state, they rod like shaped with size ranging between 98 -112µm. The FTIR spectral show no chemical interactions between the excipients and 5 FU. The yield (PY), drug entrapment efficiency (DEE) and the drug loading (DL) values were high enough to support commercial scale up of the technique. SD2 had the highest DEE, cumulative drug released and DL values. This may be responsive for its improved cytotoxicity against HT115 cells. The releases of 5 FU in all the formulations follow both Fickian´s and non-Fickian´s kinetics which are also pH responsive with no sign of dose dumping. Conclusion This study demonstrated successful production of pH responsive 5 FU solid dispersions, by hot melt technique. The release follows Korymeyer –Peppas kinetic models and selectively delivered 5 FU to the colon which improved cytotoxicity activity against CRC.

References

Afzal, S., ,Jensen, S.A,Vainer, B., Vogel, U,et al.(2009) MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol 20:1660–6.

Alonzo, D.E., Zhang, G Z., Zhou, G, Gao, Y et al (2010).Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution. Pharmaceutical Research, 27,( 4), 608-618

Amidon, S., Brown, J.E.and Dave, V.S. (2015). Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches. PharmSciTech, Vol. 16, No. 4, 731-742.

Aoife, L., Sasha, N. J. and Fional, Z. (2014) Non-malignant and Malignant Skin Lesions in Kidney Transplant Patients. In Kidney Transplantation-Principles and practice (7th edt) p 550-568. Edt: Peter M and Stuart, J. K

Babu, N..J and Nangia, A. (2011) Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals. Crystal Growth & Design 11 (7), 2662-2679

Bernas, T. and Dobrucki, J (2002).Mitochondrial and nonmitochondrial reduction of MTTwith TMRE,JC-1 and NAO mitochondrial fluorescent probes. Cytometry 47(4) 236-242

Berridge, M.V., Herst, P.M. and Tan, A.S. (2005). Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnology Annual Review, 11.127-152

Bhatnagar, P., Dhote,V., Mahajan, S.C., Mishra, P.K. and Mishra, D.K (2014). Solidersion in pharmaceutical drug development, from basics to clinical applications. Curr Drug Deliv.11: 155-171

Cirpanli Y, Yerlikaya F, Ozturk K, et al. (2010). Comparative evaluation of in vitro parameters of tamoxifen citrate loaded poly(lactide-co-glycolide), poly(epsilon-caprolactone) and chitosan nanoparticles. Pharmazie.;65(12):867–870.

Das, S., Deshmukh, R., Jha, A. (2010). Role of natural polymers in the development of multiparticulate systems for colon drug targeting. Syst Rev Pharmacy. 1(1):79–85.

De Gramont A, Figer, A., Seymour, M,. et al (2000). Leucovorin and Fuorouracil with or without Oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–47.

Gao, Y. Huo, X., Dong, L., et al (2014). Fourier transform infrared microspectroscopy monitoring of 5-fluorouracil-induced apoptosis in SW620 colon cancer cells. Molecular medicine reports 11(4) 2585 -2591.

Guo, P. Song, S, Li, Z, (2015). In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy. Int. J. Pharm. 486, 356–366.

Heng, P.W.S., Chan, L.W. Easterbrook, M.G. and Li, X. (2001). Investigation of the influence of mean HPMC particle size and number of polymer particles on the release of aspirin from swellable hydrophilic matrix tablets. J. Control Release, 76: 39-49.

Ivanov, Y.U., Leontiev, V.S., Belous, L.F et al (2017). Infrared spectra of 5-fluorouracil molecules isolated in inert Ar matrices, and their films on graphene oxide at 6 K. Low Temperature Physics 43, 492-503

Jemal, A., Ward, E.M and Johnson C.J. (2017) Annual report to the nation on the status of Cancer 1975-2014. J.Natl.Cancer Inst. 109

Korsmeyer, R.W. and Peppas, N.A. (1984). Solute and penetrant diffusion in swellable polymers. III. Drug release from glassy poly (HEMA-co-NVP) copolymers. J. Control. Release, 1: 89-98.

Leuner, C. and Dressman, J (2000). Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics 50 :47-60

Leuva, V.R., Patel, B.G., Chaudhary, D.J, Patel, J.N, et al. (2012) Oral colon-specific drug delivery system. J Pharm Res.5(4):2293–2297

Li, X., Li, R., Qian, X., Ding, Y., et al. (2008) Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Euro J Pharm Biopharm. 70(3):726–734.

Libutti, S.K, Salz, L.B, Willett CG, Levine RA.( 2015). Chapter 57: Cancer of the colon. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins

Longley, D.B., Harkin, D.P, Johnston, P.G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–8

Mesnukul, A. and Phaechamud,T (2009). Drug release through PEG-xanthan gum-lactose matrix comprising different amount of drug. Thai. Pharm. Health Sci. J., 4: 153-163.

Mork, M.E., You, Y.N., Ying, J. (2015). High prevalence of Herediatary cancer syndromes in Adolesecents and Youths Adults with colorectal cancer. J.Clinical oncology 33:3544

Oyeniyi Y.J. & Biswajit, M (2017).Formulation and In-vitro Characterisation of Fulvestrant loaded liposomes for breast cancer therapy. Nig. J. Pharm. Res. 13 (1) 1-11

Ritger, P.L. and Peppas, N.A. (1987).. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release, 5: 37-42.

Singh, G., Pai, R.S., Devi, V.K.( 2012) Response surface methodology and process optimization of sustained release pellets using Taguchi orthogonal array design and central composite design. J Adv Pharm Tech Res 3:30-40

Van Schaeybroeck S, Lawler M, Johnston B, (2014). Colorectal cancer. In: Neiderhuber JE, Armitage J.O., Doroshow, J.H., Kastan, M.B, Tepper, J.E, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier; 2014

Zhang, D.Y., Shen, X.Z., Wang, J.Y., Dong, L. et al (2008a). Preparation of chitosan-polyaspartic acid-5-fluorour-acil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice. World J. Gastroenterol. 14, 3554–3562

Zhang, N., Yin, Y., Xu, S.J., Chen, W.S., (2008b). 5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies Molecules 2008, 13(8), 1551-1569

Published

2019-06-30

How to Cite

Yinka Oyeniyi, & Nemeka D Nnamani. (2019). Preparation and Evaluation of 5 Fluorouracil solid dispersion formulations for therapeutic management of colorectal cancer (CRC). International Journal of Drug Delivery, 11(2). Retrieved from https://ijdd.arjournals.org/index.php/ijdd/article/view/326

Issue

Section

Original Research Articles